Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder

Journal of Psychiatric Research

Volumn 47, Issue 4, 2013, Pages 494-504

  O'Neill, Joseph ^a   Gorbis, Eda ^a,b   Feusner, Jamie D ^a   Yip, Jenny C ^b   Chang, Susanna ^a   Maidment, Karron M ^a   Levitt, Jennifer G ^a   Salamon, Noriko ^c   Ringman, John M ^c   Saxena, Sanjaya ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Westwood Institute for Anxiety Disorders   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Cingulate cortex; Cognitive behavioral therapy; Glutamate; Magnetic resonance spectroscopy; NAA; Obsessive compulsive disorder

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; CLONAZEPAM; ESCITALOPRAM; FLUVOXAMINE; GLUTAMIC ACID; GLUTAMINE; METHYLPHENIDATE; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PAROXETINE; RISPERIDONE; SERTRALINE;

ADULT; ANTERIOR CINGULATE; ANTERIOR MIDDLE CINGULATE CORTEX; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; INTENSIVE CARE; MALE; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THERAPY EFFECT; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 84874424686     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.11.010     Document Type: Article

References (84)

1. Arnold P.D., MacMaster F.P., Richter M.A., Hanna G.L., Sicard T., Burroughs E., et al. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in obsessive-compulsive disorder. Psychiatry Research 2009, 172(2):136-139.
2. Bartha R., Stein M.B., Williamson P.C., Drost D.J., Neufeld R.W.J., Carr T.J., et al. A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. American Journal of Psychiatry 1998, 155:1584-1591.
3. Baslow M.H. Functions of N-acetyl-l-aspartate and N-acetyl-l-aspartylglutamate in the vertebrate brain. Role in glial cell-specific signaling. Journal of Neurochemistry 2000, 75:453-459.
4. Baxter L.R., Ackermann R.F., Swerdlow N.R., Brody A., Saxena S., Schwartz J.M., et al. Specific brain system mediation of OCD responsive to either medication or behavior therapy. Obsessive-compulsive disorder: Contemporary issues in treatment 2000, 573-609. Lawrence Erlbaum Associates, Inc., Mahwah, New Jersey. W.K. Goodman, M.V. Rudorfer (Eds.).
5. Baxter L.R., Phelps M.E., Mazziotta J.C., Guze B.H., Schwartz J.M., Selin C.E. Local cerebral glucose metabolic rates in obsessive-compulsive disorder - a comparison with rates in unipolar depression and in normal controls. Archives of General Psychiatry 1987, 44:211-218.
6. Baxter L.R., Schwartz J.M., Mazziotta J.C., Phelps M.E., Pahl J.J., Guze B.H., et al. Cerebral glucose metabolic rates in non-depressed obsessive-compulsives. American Journal of Psychiatry 1988, 145:1560-1563.
7. Baxter L.R., Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry 1992, 49:681-689.
8. Benazon N.R., Moore G.J., Rosenberg D.R. Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42(11):1279-1285.
9. Biedermann S., Fuss J., Zheng L., Sartorius A., Falfán-Melgoza C., Demirakca T., et al. In vivo voxel based morphometry: detection of increased hippocampal volume and decreased glutamate levels in exercising mice. NeuroImage 2012, 61(4):1206-1212.
10. Bolton J., Moore G.J., MacMillan S., Stewart C.M., Rosenberg D.R. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. Journal of the American Academy of Child and Adolescent Psychiatry 2001, 40:903-906.
11. Brennan B.P., Rauch S.L., Jensen J.E., Pope H.G. A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biological Psychiatry 2012, http://dx.doi.org/10.1016/j.biopsych.2012.06.023.
12. Bush G., Luu P., Posner M.I. Cognitive and emotional influences in anterior cingulate cortex. Trends Cognitive Science 2000, 4:215-222.
13. Cangro C.B., Namboodiri M.A.A., Sklar L.A., Corigliano-Murphy A., Neale J.H. Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. Journal of Neurochemistry 1987, 49:1579-1588.
14. Cassidy M., Neale J.H. N-acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface of neurons and glia. Neuropeptides 1993, 24:271-278.
15. Cleva R.M., Gass J.T., Widholm J.J., Olive M.F. Glutamatergic targets for enhancing extinction learning in drug addiction. Current Neuropharmacology 2010, 8(4):394-408.
16. Danbolt N.C. Glutamate uptake. Progress in Neurobiology 2001, 65:1-105.
17. Devinsky O., Morrell M.J., Vogt B.A. Contributions of anterior cingulate cortex to behavior. Brain 1995, 118:279-306.
18. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Research: Neuroimaging 1997, 74:173-176.
19. Emmett M., Mick S., Cler J. Actions of d-cycloserine at the N-methyl-d-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991, 30:1167-1171.
20. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV patient edition (SCID-I/P) 1996, New York State Psychiatric Institute, Biometrics Research Department, New York.
21. Fitzgerald K.D., Moore G.J., Paulson L.A., Stewart C.M., Rosenberg D.R. Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder. Biological Psychiatry 2000, 47:174-182.
22. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 2005, 162:151-161.
23. Freyer T., Klöppel S., Tüscher O., Kordon A., Zurowski B., Kuelz A.-K., et al. Frontostriatal activation in patients with obsessive-compulsive disorder before and after cognitive behavioral therapy. Psychological Medicine 2011, 41:207-216.
24. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., et al. The Yale-Brown obsessive compulsive scale I: development, use, and reliability. Archives of General Psychiatry 1989, 46:1006-1011.
25. Guy W. ECDEU assessment manual for psychopharmacology 1976, Rev. (DHEW publication no. (ADM) 76-338.), NIMH, Rockville, MD.
26. Hamilton M. Diagnosis and rating scale for depression. British Journal of Psychiatry 1960, 3:76-79.
27. Hertz L., Zielke H.R. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends in Neurosciences 2004, 27(12):735-743.
28. Holmgren C.D., Mukhtarov M., Malkov A.E., Popova I.Y., Bregestovski P., Zilberter Y. Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex in vitro. Journal of Neurochemistry 2010, 112:900-912.
29. Jang J.H., Kwon J.S., Jang D.P., Moon W.-J., Lee J.-M., Ha T.H., et al. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naïve patients with obsessive compulsive disorder. American Journal of Psychiatry 2006, 163:1202-1207.
30. Kitamura H., Shioiri T., Kimura T., Ohkubo M., Nakada T., Someya T. Parietal white matter abnormalities in obsessive-compulsive disorder: a magnetic resonance spectroscopy study at 3-Tesla. Acta Psychiatrica Scandinavica 2006, 114:101-108.
31. Kozak M.J., Foa E.B. Mastery of obsessive-compulsive disorder: a cognitive-behavioral approach-therapist guide (treatments that work) 1997, Graywind Publications, New York.
32. Kwon J.S., Kim J.J., Lee D.W., Lee D.S., Kim M.S., Lyoo I.K., et al. Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 2003, 122:37-47.
33. Lütcke H., Frahm J. Lateralized anterior cingulate function during error processing and conflict monitoring as revealed by high-resolution fMRI. Cerebral Cortex 2008, 18:508-515.
34. Li K., Xu E. The role and the mechanism of γ-aminobutyric acid during central nervous system development. Neuroscience Bulletin 2008, 24(3):195-200.
35. MacMaster F.P., O'Neill J., Rosenberg D.R. Brain imaging in pediatric obsessive compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2008, 47(11):1262-1272.
36. Mirza Y., O'Neill J., Smith E.A., Russell A., Smith J., Banerjee S.P., et al. Increased medial thalamic creatine/phosphocreatine found by proton magnetic resonance spectroscopy in children with obsessive-compulsive disorder versus major depression and healthy controls. Journal of Child Neurology 2006, 21(2):106-111.
37. Mohamed M.A., Smith M.A., Schlund M.W., Nestadt G., Barker P.B., Hoehn-Saric R. Proton magnetic resonance spectroscopy in obsessive-compulsive disorder: a pilot investigation comparing treatment responders and non-responders. Psychiatry Research: Neuroimaging 2007, 156:175-179.
38. Moore G.J., MacMaster F.P., Stewart C., Rosenberg D.R. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1998, 37:663-667.
39. Moreno A., Ross B.D., Bluml S. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. Journal of Neurochemistry 2001, 77(1):347-350.
40. Nabeyama M., Nakagawa A., Yoshiura T., Nakao T., Nakatani E., Togao O., et al. Functional MRI study of brain activation alterations in patients with obsessive-compulsive disorder after symptom improvement. Psychiatry Research: Neuroimaging 2008, 163:236-247.
41. Nakatani E., Nakagawa A., Ohara Y., Goto S., Uozumi N., Iwakiri M., et al. Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 2003, 124:113-120.
42. Nordahl T.E., Benkelfat C., Semple W.E. Cerebral glucose metabolic rates in obsessive-compulsive disorder. Neuropsychopharmacology 1989, 2(1):23-28.
43. 18FDG-PET. Magnetic Resonance in Medicine 2000, 43:244-250.
44. O'Neill J., Schwartz J.M. OCD treatment: the role of volition in OCD therapy: neurocognitive, neuroplastic, and neuroimaging aspects. Clinical Neuropsychiatry 2005, 1(1):10-18.
45. O'Neill J., Sobel T.L., Vogt B.A. Localizing cingulate subregions of interest in magnetic resonance images guided by cytological parcellations. Cingulate neurobiology and disease 2009, 3-30. Oxford University Press, New York. B.A. Vogt (Ed.).
46. O'Neill J, Thomas S, Hudkins M, Dean A, Tobias MC, London ED. MRSI and a model of metabolic dysfunction in human methamphetamine dependence. In: Translational research in methamphetamine addiction conference, Pray, MT, July 21, 2010.
47. Pallanti S., Hollander E., Bienstock C., Koran L., Leckman J., Marazziti D., et al. Treatment non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology 2002, 5:181-191.
48. 18F]-FDG-PET study in obsessive-compulsive disorder: a clinical/metabolic correlation study after treatment. British Journal of Psychiatry 1995, 166:244-250.
49. Petroff O.A., Mattson R.H., Rothman D.L. Proton MRS: GABA and glutamate. Advances in Neurology 2000, 83:261-271.
50. 1H magnetic resonance spectroscopy in patients with epilepsy. Journal of Cerebral Blood Flow and Metabolism 2000, 20(5):871-878.
51. Picard N., Strick P.L. Motor areas of the medial wall: a review of their location and functional activation. Cerebral Cortex 1996, 6:342-353.
52. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR in Biomedicine 2001, 14:260-264.
53. Ringman J, O'Neill J, Tseng PB, Apostolova L, Geschwind D, SChaffer B, et al. Elevated hippocampal myo-inositol in subjects with or at-risk for familial AD. In: ICAD 2006: 10th international conference on Alzheimer's disease and related disorders, Madrid, July 15-20, 2006.
54. Robinson M.B., Blakely R.D., Couto R., Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. Journal of Biological Chemistry 1987, 262:14498-14506.
55. Rojas C., Frazier S.T., Flanary J., Slusher B.S. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Analytical Biochemistry 2002, 310:50-54.
56. Rosenberg D.R., Amponsah A., Sullivan A., Macmillan S., Moore G.J. Increased medial thalamic choline in pediatric obsessive-compulsive disorder as detected by quantitative in vivo spectroscopic imaging. Journal of Child Neurology 2001, 16:636-641.
57. Rosenberg D.R., Keshavan M.S. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biological Psychiatry 1998, 43:623-640.
58. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgeratd K.D., Stewart C.M., Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39(9):1096-1103.
59. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee P., et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43(9):1146-1153.
60. Rothbaum B.O. Critical parameters for d-cycloserine enhancement of cognitive-behavioral therapy for obsessive-compulsive disorder. American Journal of Psychiatry 2008, 165(3):293-296.
61. Sawle G.V., Hymas N.F., Lees A.J., Frackowiak R.S. Obsessional slowness: functional studies with positron emission tomography. Brain 1991, 114(Pt 5):2191-2202.
62. Saxena S., Bota R.G., Brody A.L. Brain-behavior relationships in obsessive-compulsive disorder. Seminars in Clinical Neuropsychiatry 2001, 6:82-101.
63. Saxena S., Gorbis E., O'Neill J., Baker S.K., Mandelkern M.A., Maidment K.M., et al. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Molecular Psychiatry 2009, 14(2):197-205.
64. Saxena S., O'Neill J., Rauch S.L. The role of cingulate cortex dysfunction in obsessive-compulsive disorder. Cingulate neurobiology and disease 2009, 587-618. Oxford University Press, New York. B.A. Vogt (Ed.).
65. Schwartz J.M. Brain lock: free yourself from obsessive-compulsive disorder 1996, Harper Collins, New York.
66. Schwartz J.M., Stoessel P.W., Baxter L.R., Martin K.M., Phelps M.E. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Archives of General Psychiatry 1996, 53:109-113.
67. Seese R.R., O'Neill J., Hudkins M., Siddarth P., Levitt J., Tseng B., et al. Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia. Schizophrenia Research 2011, 133:82-90.
68. Shattuck D., Sandor-Leahy S., Schaper K., Rottenberg D.A., Leahy R.M. Magnetic resonance image tissue classification using a partial volume model. NeuroImage 2001, 13:856-876.
69. 13C-NMR spectroscopy evidence for coupling of cerebral glucose consumption and glutamatergic neuronal activity. Developmental Neuroscience 1998, 20(4-5):321-330.
70. Simpson H.B., Shungu D.C., Bender J., Mao X., Xu X., Slifstein M., et al. Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology 2012, [Epub ahead of print]. 10.1038/npp.2012.132.
71. Smith E.A., Russell A., Lorch E., Banerjee S.P., Rose M., Ivey J., et al. Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study. Biological Psychiatry 2003, 54:1399-1405.
72. 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. Journal of Neural Transmission 2008, 115:1051-1062.
73. Sumitani S., Harada M., Kubo H., Ohmori T. Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients. Psychiatry Research: Neuroimaging 2007, 154:85-92.
74. Swedo S.E., Schapiro M.B., Grady C.L., Cheslow D.L., Leonard H.L., Kumar A., et al. Cerebral glucose metabolism in childhood onset obsessive-compulsive disorder. Archives of General Psychiatry 1989, 46:518-523.
75. Vogt B.A. Regions and subregions of the cingulate gyrus. Cingulate neurobiology and disease 2009, 3-30. Oxford University Press, New York. B.A. Vogt (Ed.).
76. Whalen P.J., Bush G., McNally R.J., Wilhelm S., McInerney S.C., Jenike M.A., et al. The emotional counting Stroop paradigm: an fMRI probe of the anterior cingulate affective division. Biological Psychiatry 1998, 44:1219-1228.
77. Whiteside S.P., Abramowitz J.S., Port J.D. The effect of behavior therapy on caudate N-acetyl-l-aspartic acid in adults with obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 2012, 201:10-16.
78. Whiteside S.P., Port J.D., Deacon B.J., Abramowitz J.S. A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Research: Neuroimaging 2006, 146:137-147.
79. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G., Reese H.E., et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 2008, 165:335-341.
80. Yamanishi T., Nakaaki S., Omori I.M., Hashimoto N., Shinagawa Y., Hongo J., et al. Changes after behavior therapy among responsive and nonresponsive patients with obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 2009, 172:242-250.
81. Yücel M., Harrison B.J., Wood S.J., Fornito A., Wellard R.M., Pujo J., et al. Functional and biochemical alterations of the medial frontal cortex in obsessive-compulsive disorder. Archives of General Psychiatry 2007, 64(8):946-955.
82. Yücel M., Wood S.J., Wellard R.M., Harrison B.J., Fornito A., Pujol J., et al. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. Australia-new Zealand Journal of Psychiatry 2008, 42(6):467-477.
83. Zurowski B., Kordon A., Weber-Fahr W., Voderholzer U., Kuelz A.K., Freyer T., et al. Relevance of orbitofrontal neurochemistry for the outcome of cognitive-behavioural therapy in patients with obsessive-compulsive disorder. European Archives of Psychiatry and Clinical Neuroscience 2012, 10.1007/s00406-012-0304-0.
84. Zurowski B., Weber-Fahr W., Freyer T., Wahli K., Büchert M., Kuel A.K., et al. Neurochemical abnormalities in patients with obsessive-compulsive disorder diminish in the course of behavior therapy. Society for Neuroscience Abstracts Nov 5, 2007.